EFFECT OF COMBINING LOSARTAN AND PERINDOPRIL IN DIABETIC PATIENTS WITH PROTEINURIA

Shin-chee Chin; Adyani Md Redzuan

doi:10.22159/ajpcr.2017.v10i10.20253

Authors

Shin-chee Chin Quality Use of Medicine Research Group, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
Adyani Md Redzuan Quality Use of Medicine Research Group, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i10.20253

Keywords:

Albuminuria, Losartan, Perindopril, Hypertension, Urinary albumin creatinine ratio

Abstract

Â

Â Objective: This retrospective study compared the efficacy and safety of losartan monotherapy versus losartan and perindopril combination therapy in diabetic patients with hypertension and albuminuria. Factors affecting the change in albuminuria were identified.

Methods: Through quota sampling, the study recruited patients from a tertiary care hospital. Outcome parameters included urinary albumin creatinine ratio (UACR), blood pressure (BP), serum creatinine, and estimated glomerular filtration rate (eGFR). Both pre- and post-treatment measurements were traced from patient's medical records.

Results: No significant differences (p=0.615) were detected in the pre- and post-treatment change in UACR between the monotherapy group (âˆ’38.3 mg/g, interquartile range [IQR]:âˆ’618.8-0) and combination therapy group (âˆ’88.4 mg/g, IQR: âˆ’729.3-+375.7). There was a considerably higher percentage of patients attaining the target BP of <125/75 mmHg in the combination group (66.7%; p<0.001). In terms of safety, combined losartan and perindopril caused more hypotension (p=0.003), higher rise in serum creatinine (p=0.481), and greater drop in eGFR (p=0.861). Body mass index was shown to have significant negative correlation with UACR reduction (r=âˆ’0.449; p=0.036).

Conclusion: The main finding of this study was that losartan alone was as equally efficacious as combined losartan and perindopril in lowering UACR and BP among diabetic patients.

Â

Downloads

Download data is not yet available.

References

Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15(2):276-82.

Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90(1):449-55.

National Kidney Foundation. KDOQI clinical practice guideline for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39 2 Suppl 1:S1-266.

Pham JT, Schmitt BP, Leehey DJ. Effects of dual blockade of the renin-angiotensin system in diabetic kidney disease: A systematic review and meta-analysis. J Nephrol Ther 2012;S2:003.

Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148(1):30-48.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-9.

Pfeffer MA, McMurray JJ, Velasquez EJ, Rouleau JL, KÃ¸ber L, Maggioni AP, et al. For the valsartan in acute myocardial infarction trial investigators. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1839-1906.

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60(5):850-6.

Clinical Trials at Villa Camozzi. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes. The VALID Trial. 2012. Available from: http://www.clintrials.marionegri.it/index.php/main-trials/main-trials-ongoing/70.html. [Last accessed on 2013 Feb 25].

Fried LF, Duckworth W, Zhang JH, Oâ€™Connor T, Brophy M, Emanuele N, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropath y (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4(2):361-8.

Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, micro albuminuria, and noninsulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4.

Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: Results from the ONTARGET and TRANSCEND studies. Circulation 2011;123(10):1098-7.

Vasan RS, Larson MG, Leip EP, Evans JC, Oâ€™Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345(18):1291-7.

Rossi MC, Nicolucci A, Pellegrini F, Comaschi M, Ceriello A, Cucinotta D, et al. Obesity and changes in urine albumin/creatinine ratio in patients with Type 2 diabetes: The DEMAND study. Nutr Metab Cardiovasc Dis 2010;20(20):110-6.

Bildirici U, Ural E, Kilic T, Aygun F, Acar E, Cekmen M, et al. Association between documented coronary artery disease and urinary albumin, albumin to creatinine ratio. Med Sci Monit 2010;16(11):CR545-8.

Epstein M. Aging and the kidney. J Am Soc Nephrol 1996;7(8):1106-22.